Rankings
▼
Calendar
XERS Q3 2025 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena
XERS
Xeris Biopharma Holdings, Inc.
$960M
Q3 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$74M
+37.1% YoY
Gross Profit
$63M
85.2% margin
Operating Income
$7M
9.0% margin
Net Income
$621,000
0.8% margin
EPS (Diluted)
$0.00
QoQ Revenue Growth
+4.0%
Cash Flow
Operating Cash Flow
$18M
Free Cash Flow
$18M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$370M
Total Liabilities
$371M
Stockholders' Equity
-$861,000
Cash & Equivalents
$92M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$74M
$54M
+37.1%
Gross Profit
$63M
$41M
+55.8%
Operating Income
$7M
-$13M
+152.2%
Net Income
$621,000
-$16M
+103.9%
Revenue Segments
Product
$74M
86%
Keveyis
$12M
14%
← FY 2025
All Quarters
Q4 2025 →